By proceeding, you agree to our Terms of Use and Privacy Policy.
The past year has seen several combination therapies entering Phase I and II clinical trials, with some showing promising results while others facing challenges, especially in the treatment of solid tumors. The FDA Modernization Act 2.0 has encouraged the biopharmaceutical industry to shift away from animal models, allowing for more innovation in preclinical and translational tumor models to bridge the gap between laboratory research and clinical trials.The 11th Annual Tumor Models Boston Summit offers practical insights into the latest developments in preclinical and translational targeted combination oncology. Attendees will have access to over 25 case studies presented in two dedicated tracks, providing opportunities to learn from and network with pioneers in the field. By leveraging the knowledge and expertise shared at the event, researchers can improve the translatability, efficiency, and cost-effectiveness of their candidates, ultimately advancing them to patients.
Explore cutting-edge tumor modeling techniques, emerging technologies, and innovative approaches.
Gain insights and meet pioneers in preclinical and translational targeted, combination oncology to advance your candidates to patients with optimized translatability, efficiency, and cost-effectiveness!
Dive deep through an interactive chat into bridging translatability towards patients. Apart from this, gain practical insights into the latest updates through 25+ case studies across 2 dedicated tracks.
Learn strategies for preclinical and clinical biomarker selection that will empower you to accurately predict drug combination success in patients.
Hanson Wade gives people the clarity to see where opportunity lies. We work in highly specialised fields to provide unmatched depth and quality of content. We work in sectors where quality of information is the difference between success and failure.
Tempus is making precision medicine a reality by applying AI in healthcare, deriving insights from our expansive library of clinical data and molecular data.
Translational Drug Development (TD2) is an oncology-focused Contract Research Organization (CRO) that supports improved and accelerated development of medicines for life-threatening diseases.
Certis began its journey in precision medicine, helping individual cancer patients and their oncologists determine--with certainty--the best available treatments for their unique cancers.
Kiyatec is disrupting cancer care by accurately predicting patient–specific response and non–response before treatment begins.
Clear and confident health care decisions begin with questions. At Labcorp, we’re constantly in pursuit of answers.
FibroFind is a rapidly developing biomedical sciences company that has a deep understanding of fibrosis biology and has employed this knowledge to design bespoke biological assays with human tissues that can determine if a novel drug is able to preve
Champions Oncology, Inc. provides an end-to-end range of research and development solutions and services that improve the productivity of oncology drug development.
XenoSTART is an industry-leading oncology translational research organization focused on the development and utilization of PDX models. Founded in 2007, XenoSTART was created in close collaboration with The START Center, an international cancer trea
XenoSTART is an industry-leading oncology translational research organization focused on the development and utilization of PDX models. Founded in 2007, XenoSTART was created in close collaboration with The START Center, an international cancer treatment and research organization. This partnership
GemPharmatech Co. Ltd., founded in 2017, is an international biotechnology enterprise specializing in the development of humanized animal models. The management and operation team has nearly 20 years of experience in gene-editing technology and anima
GemPharmatech Co. Ltd., founded in 2017, is an international biotechnology enterprise specializing in the development of humanized animal models. The management and operation team has nearly 20 years of experience in gene-editing technology and animal production. GemPharmatech provides a one-stop se
All trademarks, registered trademarks, product names, and company names or logos mentioned in or on this site are the property of their respective owners.
A great community. Legit content. The kind of emails you actually look forward to.